Proactive Investors - Run By Investors For Investors

Genedrive's Hepatitis C test is quick, effective and simple to use, say analysts

The diagnosis of Hepatitis C is a multi-million-dollar market opportunity
Hepatitis C ID Kit tests the virus more quickly and easily than other products on offer

Genedrive PLC’s (LON:GDR) offers a rapid, low-cost, simple-to-use device with high sensitivity and specificity in testing for Hepatitis C, according to analysts at Hardman & Co. 

The analysts said the company’s first half sales were ahead of forecasts as it made progress with its Hepatitis C (HCV) ID Kit, which was launched at the IFCC World Lab conference in South Africa in October.

READ: Genedrive making “good progress” as it hurtles towards commercialisation of its hep C test

The kit tests for the virus much more quickly and easily than other products currently on offer.

Hardman & Co said the diagnosis of HCV is a multi-million-dollar market opportunity. 

“The hepatitis C market is a global opportunity, very large even in developing countries. With a strong commercial partner now in place, early evidence of sales traction will highlight the valuation anomaly,” it said.

In September, the kit was awarded a CE mark, meaning it could be sold into Europe and other countries that accept this certification.

"Now that the Genedrive technology platform has received CE Mark, the new management team has completely re-focused the company onto the commercialisation pathway for diagnosis of infectious diseases, signing two important commercial agreements with Sysmex, a major global player," Hardman & Co said.

READ: Genedrive’s Hep C diagnostic device excels in African performance study

Distribution partner, Sysmex, has successfully completed the first field study in Africa. The results of the study were published earlier this week, revealing the “robust performance” of the handheld device in a third party setting and on territory specific examples.

"Genedrive technology ticks all the boxes described for an ‘ideal’ in vitro diagnostic that satisfies the need for powerful molecular diagnostics outside the hospital setting," Hardman & Co said.

Sales in the six months to the end of December fell to £2.6mln from £2.88mln the same period a year ago. The company ended the period with a strong-than-expected cash balance of £4.6mln.

"The next six months are set to be an exciting period for Genedrive PLC as the company transitions to commercialisation of its diagnostics products," Hardman & Co. said.

"It remains on track to report full-year sales in line with our forecasts (£5.1m), which include a boost to the diagnostics business from the first sales of the Genedrive HCV ID platform and kits to its distributer, Sysmex, towards the end of the second half."

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
November 23 2018
The Australian regenerative medicine company is developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence-driven strategy.
October 19 2018
Respiratory syncytial virus causes the common cold, for which there is no effective cure.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use